JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Home・Akcijų sąrašas・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

13.16 8.76

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.95

Max

13.29

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.8M 22M
Pardavimai	7.5M 70M
P/E Sektoriaus vid.	28.581 37.003
Pelno marža	30.729
Darbuotojai	130
EBITDA	6.3M 28M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+0.66% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	417M 1.6B
Ankstesnė atidarymo kaina	4.4
Ankstesnė uždarymo kaina	13.16

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

8.1 / 8.21 Palaikymas ir pasipriešinimas

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-31 17:40; UTC

Įsigijimai, susijungimai, perėmimai

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

2025-10-31 23:09; UTC

Uždarbis

Review & Preview: October Surprise -- Barrons.com

2025-10-31 22:44; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

2025-10-31 21:25; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

2025-10-31 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

2025-10-31 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

2025-10-31 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-31 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-31 20:50; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2025-10-31 20:46; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

2025-10-31 20:22; UTC

Uždarbis

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

2025-10-31 20:02; UTC

Uždarbis

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

2025-10-31 19:55; UTC

Rinkos pokalbiai

Crude Futures Fall for Third Straight Month -- Market Talk

2025-10-31 19:54; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

2025-10-31 19:54; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

2025-10-31 19:26; UTC

Rinkos pokalbiai

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

2025-10-31 18:30; UTC

Uždarbis

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

2025-10-31 18:23; UTC

Rinkos pokalbiai

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

2025-10-31 18:09; UTC

Uždarbis

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

2025-10-31 18:08; UTC

Uždarbis

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

2025-10-31 17:36; UTC

Rinkos pokalbiai

Grain Futures Shrug Off Stronger Dollar -- Market Talk

2025-10-31 17:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

2025-10-31 17:16; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Acquisition Likely Completed in First Half Next Year

2025-10-31 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Agreement Set to Be Signed By Year-Out

2025-10-31 17:14; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Acquisition Will Strengthen Position in Spain

2025-10-31 17:13; UTC

Įsigijimai, susijungimai, perėmimai

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

2025-10-31 17:12; UTC

Įsigijimai, susijungimai, perėmimai

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

0.66% į viršų

12 mėnesių prognozė

Vidutinis 12.2 USD 0.66%

Aukščiausias 17 USD

Žemiausias 10 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aurinia Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Aurinia Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.1 / 8.21Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.